Search results
Results From The WOW.Com Content Network
Long-term administration of spironolactone gives the histologic characteristic of "spironolactone bodies" in the adrenal cortex. Spironolactone bodies are eosinophilic , round, concentrically laminated cytoplasmic inclusions surrounded by clear halos in preparations stained with hematoxylin and eosin .
Unlike spironolactone, bicalutamide has no antimineralocorticoid activity, [97] and for this reason, has no risk of hyperkalemia (which can, rarely/in severe cases, result in hospitalization or death) [112] or other antimineralocorticoid side effects such as urinary frequency, dehydration, hypotension, hyponatremia, metabolic acidosis, or ...
Spironolactone has been identified as an inhibitor of NRG1‐ERBB4 signaling. [142] Spironolactone has been found to act as a potent inhibitor of the pannexin 1 channel, and this action appears to be involved in its antihypertensive effects independently of MR antagonism. [143] Spironolactone has been found to block hERG channels. [144]
However, spironolactone is metabolized to three active metabolites, which give it prolonged activity (13.8 – 16. 5 hours). Spironolactone has a long half-life and is excreted 47-51% through kidneys. Patients with chronic kidney disease therefore require close monitoring when taking the drug. Spironolactone is also eliminated through feces (35-41%
Some common testosterone-blocking medications that most use before undergoing orchiectomy are spironolactone and cyproterone. Common side effects caused by spironolactone are drowsiness, confusion, headache, fatigue, nausea/vomiting, gastritis , polyuria , polydipsia , and electrolyte imbalance ( hyperkalemia ).
AOL latest headlines, entertainment, sports, articles for business, health and world news.
1957: The steroidal antiandrogen spironolactone is first synthesized [219] 1960: Spironolactone is first introduced for medical use, as an antimineralocorticoid [219] 1961: The steroidal antiandrogen cyproterone acetate is first synthesized [220] 1962: Spironolactone is first reported to produce gynecomastia in men [219] [221]
In general, large-scale studies do tend to show that long-term use of antidepressants is associated with weight gain side effects. However, study data on escitalopram and weight changes is very ...